Navicixizumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameNavicixizumab
Drug Alias Nameanti-DLL4/VEGF bispecific antibodyOMP-305B83
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor inhibitorsDelta-like protein 4 inhibitors
TargetsVascular endothelial growth factorDelta-like protein 4
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsOvarian Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesOncomed Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesQiagen NVCelgene CorpOncologie Inc +[4] 
Inactive CompaniesOncomed Pharmaceuticals Inc
Active IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsStomach Neoplasms +[6] 
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A